S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:FLXN

Flexion Therapeutics (FLXN) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)
Free FLXN Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$9.12
▼
$9.12
50-Day Range
$9.12
▼
$9.44
52-Week Range
$4.30
▼
$13.66
Volume
N/A
Average Volume
1.18 million shs
Market Capitalization
$458.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
FLXN stock logo

About Flexion Therapeutics Stock (NASDAQ:FLXN)

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

FLXN Stock News Headlines

April 19, 2024 | finance.yahoo.com
Flexion awarded contract to revolutionize Head Start’s Data Management System
April 11, 2024 | tmcnet.com
Flexion Joins AWS Public Sector Partner Program, Enhancing Commitment to Public Sector Software Projects
April 19, 2024 | Behind the Markets (Ad)
The #1 Opportunity of the decade?
It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.
April 6, 2024 | seekingalpha.com
VIRI Virios Therapeutics, Inc.
February 14, 2024 | morningstar.com
Spyre Therapeutics Inc SYRE
February 10, 2024 | benzinga.com
PFIZER INC's Net Worth
November 24, 2023 | benzinga.com
SpringWorks Therapeutics Stock (NASDAQ:SWTX), Analyst Ratings, Price Targets, Predictions
July 11, 2023 | benzinga.com
Flexion wins MCADS contract to modernize CMS Claims Handling System
April 19, 2024 | Behind the Markets (Ad)
The #1 Opportunity of the decade?
It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.
July 10, 2023 | finance.yahoo.com
Flexion achieves Select Tier Status within the AWS Partner Network
June 10, 2023 | yahoo.com
7 Exercises to Stretch Plantar Flexion Movement
May 16, 2023 | marketwatch.com
2023-2029 Flexion Tires Market Growth Prospects and Countries Analysis | with 91 Pages
May 4, 2023 | finance.yahoo.com
OPPO Find N2 Flip's Flexion Hinge Marks A Breakthrough In Flip Phone Experience
April 28, 2023 | marketwatch.com
Prone Leg Flexion Trainers Market Global Outlook and Projection till 2029
April 12, 2023 | marketwatch.com
Abdominal Flexion Training Device Market Research & Size Analysis 2023-2028
April 6, 2023 | marketwatch.com
Prone Leg Flexion Trainers Market 2023 Huge Demand, Growth Opportunities and Expansion by 2031
March 23, 2023 | marketwatch.com
Global Flexion Tires Market: Future Extrapolations and Emerging Updates for 2023-2027
February 24, 2023 | msn.com
Oppo’s new Flexion hinge has made flip phones more practical and crease minimal
September 21, 2022 | seekingalpha.com
PCRX Pacira BioSciences, Inc.
September 1, 2022 | thestreet.com
Coherus BioSciences Inc. News
August 17, 2022 | venturebeat.com
Flexion targets TikTok influencers on behalf of game developers
July 2, 2022 | thestreet.com
Biotech Movers: Akebia Soars on Expanded Partnership With Otsuka
January 13, 2022 | thestreet.com
Why Flexion Therapeutics (FLXN) Stock Is Plummeting in After-Hours Trading Today
November 3, 2021 | finance.yahoo.com
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark
November 1, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations
October 30, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flexion Therapeutics, Inc. - FLXN
October 30, 2021 | prnewswire.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flexion Therapeutics, Inc. - FLXN
See More Headlines
Receive FLXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/12/2021
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FLXN
CUSIP
N/A
CIK
1419600
Web
www.flexiontherapeutics.com
Phone
(781) 305-7777
Fax
781-202-3399
Employees
257
Year Founded
2007

Profitability

EPS (Most Recent Fiscal Year)
($2.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-113,710,000.00
Net Margins
-100.32%
Pretax Margin
-100.32%
Return on Equity
N/A
Return on Assets
-44.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.38
Quick Ratio
4.05

Sales & Book Value

Annual Sales
$85.55 million
Price / Sales
5.36
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.34) per share
Price / Book
-26.82

Miscellaneous

Outstanding Shares
50,321,000
Free Float
45,727,000
Market Cap
$458.93 million
Optionable
Optionable
Beta
1.53

Social Links

Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Michael D. Clayman
    President, Chief Executive Officer & Director
  • Fred Driscoll
    Chief Financial Officer
  • William T. Andrews
    Chief Medical Officer
  • Carolyn Beaty Scimemi
    Chief Compliance Officer & Head-Legal Affairs
  • Christina WillwerthChristina Willwerth
    Chief Strategy Officer

Key Competitors

View All Competitors

FLXN Stock Analysis - Frequently Asked Questions

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced its quarterly earnings results on Wednesday, May, 12th. The specialty pharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.08. The specialty pharmaceutical company earned $24.59 million during the quarter, compared to analysts' expectations of $24.61 million.

What is Mike Clayman, MD's approval rating as Flexion Therapeutics' CEO?

46 employees have rated Flexion Therapeutics Chief Executive Officer Mike Clayman, MD on Glassdoor.com. Mike Clayman, MD has an approval rating of 85% among the company's employees.

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM).

This page (NASDAQ:FLXN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The #1 Crypto for 2024
InvestorPlace
Your Money is Not Safe
American Alternative